CT 2576

CT 2576 (2-8 μM; 1 h) inhibits Tat (HY-P0281)-induced phosphatidic acid (PA) accumulation in 293tat cells^[1].
CT 2576 (4-32 μM; 24 h) inhibits HIV LTR-mediated gene expression activated by Tat and TNF-α (HY-P704246) in 293tat and 293tat3 human embryonic kidney cells, with an IC₅₀ of 8-10 μM^[1].
CT 2576 (for 4 days) inhibits constitutive, TNF-α-induced, and IL-6 (HY-P704644)-induced HIV-1 p24 antigen expression in U1 human promonocytes, with an IC₅₀ of approximately 1 μM^[1].
CT 2576 (up to 12.5 μM; 24 h) potently inhibits the proliferation of malignant T-cell lymphoma cell lines PB-1, 2A, 2B and phytohemagglutinin (PHA)-stimulated PBMCs, with an IC₅₀ of 2-3 μM^[2].
CT 2576 (2-16 h) inhibits constitutive tyrosine phosphorylation of Jak3 and STAT5 in a time-dependent manner in malignant T cells (PB-1, 2A, 2B)^[2].
CT 2576 (8-16 h) inhibits IL-2 (Y-P7037B)-induced Jak3 phosphorylation in IL-2-dependent SZ-4 cells, and partially suppresses constitutive tyrosine phosphorylation of multiple cellular proteins in 2B cells^[2].
CT 2576 (12 μM; pretreated for 30 min followed by 18 h of stimulation) has no effect on NF-κB activation or AP mRNA transcription in 293tat cells co-treated with TNF-α or IL-1β (HY-P704378)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.